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Abstract 
Alisporivir is a cyclophilin inhibitor with demonstrated in vitro and in vivo activity against hepatitis C 
virus (HCV). We estimated antiviral effectiveness of alisporivir alone or in combination with pegylated-
Inteferon (peg-IFN) in 88 patients infected with different HCV genotypes treated for four weeks. The 
pharmacokinetics of both drugs were modeled and used as driving functions for the viral kinetic model. 
Genotype was found to significantly affect pegylated-Inteferon effectiveness (ε= 86.3% and 99.1% in 
genotype-1/4 and genotype-2/3, respectively, p<10-7) and infected cells loss rate (= 0.22 vs 0.39 day-1 
in genotype-1/4 and genotype-2/3, respectively, p<10-6). Alisporivir effectiveness was not significantly 
different across genotype and was high for doses ≥600 mg QD. We simulated virologic responses with 
other alisporivir dosing regimens in HCV genotype-2/3 patients using the model. Our predictions 
consistently matched the observed responses, demonstrating that this model could be a useful tool for 
anticipating virologic response and optimize alisporivir-based therapies. 
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Introduction 
Chronic infection with hepatitis C virus (HCV) affects about 170 million people worldwide and is 
responsible for the majority of morbidity and mortality from liver diseases.1 The goal of treatment is to 
achieve a sustained virologic response (SVR), marker of viral eradication, assessed by the absence of 
detectable HCV RNA six months after treatment cessation. Over the last few years, a rapid development 
of direct acting antivirals (DAAs) has opened a new era for HCV therapy. The advent of the new 
therapies has dramatically increased SVR rate and decreased treatment duration. In recent phase 3 
clinical trials including a protease or a polymerase inhibitor, SVR was higher than 90% following a 12 
week-treatment. This holds the expectation that several one-in-a-pill (i.e., interferon-free) treatments 
with universal cure might be achieved.2,3 However several challenges are still ahead. First DAAs have 
been optimized to treat HCV genotype-1 and have lower effectiveness against genotypes2/3, which 
account for 19 to 40% of HCV-infected patients. Second, high mutation rate of HCV of several DAA 
classes (i.e. protease and non-nucleoside polymerase inhibitors) requires therapies with a high barrier to 
resistance, which can be achieved by combining several antiviral agents.2,4 However therapy 
combination can be a particularly difficult endeavor and requires anticipating possible pharmacokinetic-
pharmacodynamic (PK-PD) interaction between different agents.  
Unlike DAAs that specifically block a viral protein, host targeting antivirals (HTA) block host 
proteins necessary for viral replication.2 Alisporivir, a second-generation cyclophilin inhibitor devoid 
of immunosuppressive activity, is the most advanced HTA.2,5 Alisporivir acts primarily by blocking in 
a dose-dependent manner the interaction between cyclophilin A and the HCV NS5A protein.5 It has 
shown potent anti-HCV activity across various HCV genotypes in several in vitro and in vivo studies.5–
7 Alisporivir was also found to have a high genetic barrier to resistance.8 In a phase 2a study (DEB-025-
HCV-203, Euract number: 2006-002695-17), the virologic response to alisporivir monotherapy or in 
combination with pegylated interferon (peg-IFN) was studied in 90 patients infected with HCV genotype 
1, 2, 3 or 4.9 Alisporivir (200, 600, and 1000 mg given BID for one week then QD till the end of 
treatment) showed a  dose-dependent antiviral effect in combination with peg-IFN, with mean viral 
decay of more than 4 and 5 log10IU/mL at week 4 in HCV genotype1 and genotype-2/3, respectively.9 
However, multiple factors involved (genotypes, monotherapy vs combination, alisporivir doses) made 
it difficult to anticipate the effect of different alisporivir dosing regimen on longer time period.  
Mathematical models for HCV kinetics have provided important insights into HCV life cycle 
as well as the effectiveness and the mechanisms of action of different anti-HCV agents .10–14 The 
understanding of virologic response can be further improved by incorporating PK information.11,15 
However this approach became more complicated in drug combination as both PK and PD interaction 
can occur. Here we incorporated the PK of alisporivir and peg-IFN into a viral kinetic (VK) model to 
estimate the antiviral effectiveness of both agents and to tease out the effect of genotypes and alisporivir 
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doses on the virologic response. Lastly we evaluated the robustness of our model by comparing the 
predictions of the model and virologic responses observed in a phase 2b study (VITAL-1, 
clinicaltrials.gov ID: NCT01215643), where alisporivir was given at different dosing regimens with 
response-adapted treatments. 
Results 
Data  
The study population comprised 90 HCV patients, 57.8% were men and 66.7% were infected with HCV 
genotype-1. Baseline and patients characteristics are presented in Table S1.9  
This was a randomized, double-blind, placebo-controlled phase 2 study in treatment naïve HCV 
patients with compensated liver function. Patients were randomized into 5 treatment arms receiving peg-
IFNα2a (180 μg/week) combined with placebo, 200, 600 or 1000 mg alisporivir or 1000 mg alisporivir 
monotherapy (Arm PEG, A, B, C, D, respectively). Alisporivir was administered as twice daily (BID) 
for one week, followed by once daily (QD) for three weeks. No lack of compliance was reported. 
Alisporivir and peg-IFN plasma trough concentrations were determined on days 1, 8, 15, 22, 29, and 50 
(21 days after the last dose). In addition,  a 12-hour and 24-hour PK of alisporivir and peg-IFN was 
established on days 1 and 29 in a subset of patients. Plasma concentrations of alisporivir and peg-IFN 
were determined using validated LC/MS/MS and ELISA assays with the limit of quantification (LOQ) 
of 2.5 ng/mL and 0.17 ng/mL, respectively.16 HCV RNA levels (IU/mL) were determined by the Roche 
COBAS TaqMan, Roche laboratories, Basel, Switzerland with LOQ of 15 or 45 IU/mL and detection 
limits of 10 or 15 IU/mL.  
The PK model of alisporivir was developed using 858 observations from 50 patients with rich 
design and 104 observations from 21 patients with sparse sampling. Seven post-dose concentrations 
recorded as trough concentrations were excluded from the analysis.  
 The PK model of peg-IFN was developed using 527 observations from 48 patients with rich 
design and 100 observations from 21 patients with sparse design.  
The VK model was developed using on- and post-treatment data (521 viral loads from 88 
patients). Two patients having no PK record for both alisporivir and peg-IFN were excluded. The 
percentages of viral load below quantification limits were 27.6%. 
Alisporivir PK model 
Alisporivir PK on day 29 was described well using a two-compartment model with delayed first-order 
absorption and Michaelis-Menten elimination (Table S2). However, this model over predicted 
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alisporivir PK profile on day 1 (Figure S1). This discrepancy between day 1 and day 29 PK was 
described using a time-dependent bioavailability. The structural model is described as below: 
 ( ) =    + (     −	  )(1 − exp	(−   ) 
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where F(t) is the bioavailability at time t. A, Q1, Q2 are the drug quantity at the absorption site, in central 
and peripheral compartment, respectively. As the bioavailability could not be identified using only oral 
data, we fixed F0 at the value found in monkeys (0.27).The relative bioavailability reached its maximal 
value in approximately 4 days (kf). The maximal relative bioavailability (Finf) was approximately 3-fold 
higher as compared to the base line value (F0). We also tested time-decreasing Vm or time-increasing 
Km models but their Bayesian Information Criterion (BIC), a criterion for model selection based on the 
log-likelihood penalized by number of parameters and observations (the lower the better), were much 
higher, compared to time-dependent bioavailability (Table S3). 
However, alisporivir exposure following 1000 mg QD was higher at day 29 in the combination 
therapy as compared to monotherapy. In order to describe this higher exposure we tested a possible peg-
IFN effect on alisporivir PK (peg-IFN effect on Vm, Km and Finf). A statistically significant effect of peg-
IFN on reducing alisporivir elimination at the dose of 1000 mg QD was described by decreasing both 
Vm (55 vs 115 mg.h-1, p<0.003) and Km (0.64 vs 2.44 mg.L-1, p<0.00023). Peg-IFN effect on the Km 
and Vm led to 1.2-time increase in the median value (or 1.5-time increase in the mean value) of AUC 
on day 29. The parameter estimates for alisporivir PK were shown in Table 1.  
Peg-IFN PK model 
The PK of peg-IFN was described by one-compartment model with linear absorption and elimination. 
alisporivir had no significant effect on peg-IFN PK (Table 1). 
PK-VK model 
The shrinkages of PK individual parameters (computed from ratio of variances) were higher than 50% 
for some PK parameters of alisporivir such as ka (58%), k12 (77%), Vm (58%), Km (51%) and Finf (60%) 
as there were 21 out of 71 patients having only weekly assessed trough concentrations. However, using 
individual PK profiles predicted from the individual parameters, the PK-VK model fitted to the viral 
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load data very well and was able to describe the fluctuation in virologic response due to the variation of 
concentrations over the dosing period (Figure 3). 
HCV genotypes were found to significantly affect both the effectiveness of peg-IFN and the 
loss rate of infected cells but not the effectiveness of alisporivir (Table 1). The average effectiveness of 
peg-IFN in the seven days following the last dose was higher in genotype-2/3 than in genotype-1/4 
patients with median values of 99.1% and  86.3% , respectively (p<10-8). Likewise the loss rate of 
infected cells, , was higher in HCV genotype-2/3 than in genotype-1/4 patients (0.39 day-1 vs  0.22 day-
1, respectively, p<10-6). Alisporivir effectiveness reached the highest values at the end of BID dosing 
during week 1 with a median value of 71.3%, 95.2%, 97.6% and 95.7% in arms A, B, C and D 
(alisporivir 200 mg, 600 mg, 1000 mg with peg-IFN and alisporivir 1000 mg monotherapy),  
respectively and then dropped when switching to QD dosing with a median effectiveness at the last day 
of treatment of 50.5%, 89.4%, 97.1% and 93.6% in arm A, B, C and D, respectively. Higher alisporivir 
effectiveness in combination than in monotherapy (median ε=97.6% vs 95.7% at day 8 and 97.1% vs 
93.6% at day 29, respectively) was explained by higher exposure of alisporivir due to PK interaction 
between the two drugs. Given in combination, alisporivir and peg-IFN acted additively and yielded to 
high effectiveness, with mean effectiveness at day 29 in HCV genotype-2/3 patients equal to 98.5%, 
99.3% and 99.5% in arm A, B and C, respectively as compared to 92.0%, 96.1% and 99.3% in genotype-
1/4 patients in arm A, B and C, respectively. The VK in different treatment arms and in two genotype 
populations was illustrated in Figure 4. 
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External validation 
We used the PK-VK model to simulate virologic responses and compared them to the results from the 
VITAL-1 study (see Methods). The observed responses were included within the 95% prediction 
interval in the large majority of cases evaluated (Table 2). Likewise a good match was also obtained for 
later data points (after week 6) where treatment regimen depended on the initial virologic response.  
Discussion 
Models of HCV kinetics have become valuable tools to estimate antiviral effectiveness and optimize 
therapy.10,17–19 Initially developed for peg-IFN/ribavirin they have been recently applied to various 
classes of DAA agents.10,12 However most of the results published considered constant treatment 
effectiveness over time and/or empirical function to describe varying-effectiveness models.11,12,15,20 In 
fact there have been only a few attempts to include PK into VK models, even less in drug combinations.21 
This, indeed, considerably complicates the analysis as interactions are susceptible to occur both at the 
PK and PD levels. Here we characterized the VK obtained in a phase 2a study using both alisporivir and 
peg-IFN PK information. 
Alisporivir PK model was developed via several steps. First a structural model using day 29 
data was developed. A two-compartment model with Michaelis-Menten elimination was the best to 
describe these data, consistent with the nonlinearity in alisporivir PK reported in  previous studies.22,16 
This model (based on day 29 data) systematically over-estimated the concentrations of alisporivir after 
the first dose on day 1. This overestimation could be due to a time-varying PK or to non-linearity in 
absorption and/or distribution and/or elimination that was not yet properly handled. To correctly identify 
the cause for this overestimation and to build a more mechanistic PK model for alisporivir, further data 
such as IV data and more detailed PK profiles during treatment would be required. We modeled the 
discrepancy of PK between day 1 and 29, using an empirical model allowing PK parameters (Vm, Km 
and bioavailability) to change with time. The model assuming time-dependent bioavailability was the 
best statistical model to describe the full PK profile. Here we chose to model the change in exposure, 
which may be the consequences of changes in bioavailability and/or distribution volume, using a time-
varying bioavailability. The relevance of this model can be explained by the fact that as alisporivir 
concentration increases, the transporters involved in the absorption and tissue distribution of alisporivir 
(P-gp, MRP2, OATP1B1, OATP1B3, NTCP, BSEP) could be inhibited.7 This would increase alisporivir 
plasma concentration (by increasing bioavailability and reducing the uptake to the liver and other 
distribution sites) and hence, increase bioavailability.  
The effect of peg-IFN on alisporivir PK was investigated by adding peg-IFN as a covariate on 
alisporivir PK parameters. Peg-IFN decreases both Vm and Km. Indeed, IFN was shown to affect the 
activity and the expression of the cytochrome P450 system23–27 and of several drug transporters such as 
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P-gp, MRP2, MRP3, BCRP, BSEP in human hepatocytes.27–29 These proteins are all involved in the 
elimination of alisporivir, via metabolism (mainly by CYP3A4) or excretion via the bile as parent drug. 
Although the mechanism for the PK interaction between alisporivir and peg-IFN remains unclear, it 
could be in part explained by the inhibition effect of peg-IFN on the CYP450 system, possibly on 
CYP3A, and on drug transporters such as P-gp. This hypothesis is also supported by the case of 
telaprevir, another substrate of CYP3A and P-gp30, where plasma exposure tends to increase in presence 
of peg-IFN.31,32 However, this interaction was evaluated using only an alisporivir dose of 1000 mg and 
additional monotherapy dosing cohorts are needed to evaluate whether this effect is universal or specific 
to this dosing regimen. Also, in this analysis, we did not account for the fluctuation in peg-IFN exposure 
that may influence the drug-drug interaction. 
Peg-IFN PK is well described with a one-compartment model. The parameters obtained were 
close to what had been reported during peg-IFN/ribavirin therapy.33–35 
We used estimated individual parameters to predict individual PK profiles of both drugs and 
these predictions were incorporated into a VK model to fit on- and post-treatment viral load data. A 
more rigorous approach could be to simultaneously fit PK and VK. However the sequential approach 
has been shown to lead to limited bias while being much less time-consuming than simultaneous 
approach.36 
To examine if the model can explain well the VK in each treatment arm, we used plots of 
prediction discrepancies versus time. Prediction discrepancies are simulation-based evaluation metrics, 
similar to visual predictive check (VPC) but unlike VPC, the heterogeneity in covariate values are 
handled in their computation 37–39. Therefore, we can use one prediction discrepancies plot for all data 
from all genotypes instead of splitting data into genotype-1/4 and 2/3 groups (with 12 and 6 patients, 
respectively) to make two VPC plots for each treatment arm. Assuming a Bliss independence model for 
the combined effect, we obtained satisfactory prediction discrepancies plots for all treatment arms 
(Figure 5), which indicated that this model without PD interaction was sufficient to characterize the 
combined effect. Although a slightly synergistic effect was observed in vitro,40 the data of this study did 
not allow ruling out any significant synergy. 
With this PK-VK model, the improved virologic response observed in HCV genotype-2/3 
patients receiving dual-therapies was attributed to a larger loss rate of infected cells ( = 0.39 day-1 vs 
0.22 day-1 in genotype-2/3 and genotype-1/4, respectively, p=10-6) and a lower IC50peg-IFN than in 
genotype-1/4 patients (0.146 µg.L-1 vs 2.26 µg.L-1, corresponding to 99.1% vs 86.3% for peg-IFN, p=10-
8). These results are consistent with previous studies comparing VK parameters between HCV genotype-
2/3 and genotype-1/4 patients with peg-IFN/ribavirin.41,42 Our analysis revealed that the loss rate of 
infected cells in the alisporivir monotherapy arm was also larger in genotype-2/3 patients (=0.41 in 
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genotype-2/3 vs 0.23 day-1 in genotype-1/4 patients, respectively, p<10-11), supporting that larger loss 
rate of infected cells was probably inherent to HCV genotypes and independent from the drug. In 
contrast, we could not show any significant effect of HCV genotypes on alisporivir effectiveness; 
however this effect was associated with a large confidence interval. Further studies with an appropriate 
design allowing better estimation of antiviral effectiveness, i.e., with frequent sampling in the first 3 
days of treatment,43 are needed to correctly evaluate this effect. Altogether our analysis suggested that 
the larger response observed in HCV genotype-2/3 receiving alisporivir monotherapy was due to an 
intrinsically larger loss rate of infected cells and not to a differential effect of alisporivir in blocking 
virus production. 
Next, in order to validate our model on an independent dataset, we used our model to predict 
the early virologic response (until week 12) with the design of the VITAL-1 study, where alisporivir 
was given in combination with ribavirin or peg-IFN for 24 weeks. To do this, two main simplifications 
were made. First, the effect of ribavirin was neglected, consistent with the hypothesis that ribavirin 
primarily acts against drug-resistant virus and has no or low effect on drug-sensitive virus.44,45 Second, 
our model was built on short term data until day 29 where no resistance-related viral breakthrough was 
observed. Therefore we excluded from our analysis patients treated with alisporivir monotherapy 
without ribavirin where significant prevalence of non-PK related suboptimal response (18 among 83 
patients, corresponding to 21.5%)22 was reported which requires to incorporate other mechanisms such 
as resistance. 
Therefore three dosing regimens were considered, two with alisporivir/ribavirin (600 or 800 mg 
QD) and one with alisporivir/peg-IFN (600 mg QD). The prediction was complicated by the response-
adapted treatment strategy. Interestingly, our predicted proportions of patients with undetectable virus 
matched very well the observed results in all groups, including the IFN-free regimen. A small  
discrepancy between predictions and observations was noticed at week 6, where we slightly 
overestimated the proportion of patients with undetectable HCV RNA in the group receiving alisporivir 
800 mg without IFN (57.4% vs 45.0%). Nevertheless, the observed response was probably artefactually 
low, as hinted by the fact that it was 5 points less than that observed with alisporivir 600 mg without 
IFN. Our model also predicted slightly lower responses at week 12 for these two IFN-free arms (~93% 
vs 98% observed in VITAL-1) and this under-prediction could be explained by the fact that ribavirin 
could help to improve the second phase decline in patients whose responses to peg-IFN are low while 
in the simulation, we ignored this effect of ribavirin on add-on peg-IFN treatment.   
Given the robustness of our early predictions, we extrapolated the proportion of patients 
considered as cured after 24 weeks of treatment, using a theoretical cure boundary. This cure boundary 
is a theoretical threshold for viral eradication, defined as less than one viral particle or infected cell 
remaining in 15L of extracellular fluid46. It was shown to provide good predictions for SVR in previous 
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studies.46,47 Here as well our predictions nicely matched reported results (Table 2). Our simulations also 
suggested that treatment duration could be optimized using early virologic response.  
In conclusion, we introduced a PK-VK model for drug combination. This model could well 
describe VK observed with different dosing groups of alisporivir given alone or with peg-IFN. Moreover 
this model provided good predictions for both early and long-term response of another study. Overall 
our approach demonstrates the use of mathematical modeling to anticipate treatment outcome in the 
coming era of oral combinations therapy for chronic HCV infections.  
Methods 
Alisporivir PK structural model 
We built the structural model using frequent sampling PK data at day 29 (steady-state) in patients 
receiving alisporivir/peg-IFN . For this, we tested one-, two-, three-compartment models, linear and 
Michaelis-Menten elimination, linear absorption with or without a latent time. We then included day 1 
data and trough concentrations obtained in this subset of patients to characterize the change in PK over 
time. This was achieved by allowing the elimination parameters and the apparent bioavailability to 
change over time:  
 ( ) = 	   −       −    (exp(−   ) − 1) 
where (t) is value of the concerning parameter  at time t, 0 is the value at time 0, inf  is the 
maximum/minimum value achieved at infinity and k is the changing rate.    
Peg-IFN PK structural model 
A one-compartment model was fitted to all the available data.33–35  
PK interaction 
Once the PK structural models of both alisporivir and peg-IFN were determined, the impact of alisporivir 
or peg-IFN on the other drug was evaluated by including alisporivir (yes/no), peg-IFN (yes/no) as a 
covariate.  
PK individual parameters 
After PK models for both drugs were obtained, individual parameters were retrieved as the Empirical 
Bayes Estimates (EBEs). The PK predictions obtained with these EBE and dosing information were 
used as driving functions in VK model. 
Viral kinetic modeling 
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The following VK model was fitted to viral load data: 
  
  
=     − 	   
  
  
= (1 −  )   −    
where T, I and V represent target cells, infected cells and free virus, respectively. We assumed a constant 
liver volume (i.e., T+I) during the study period. Infected hepatocytes die at rate δ and release virions at 
a rate p	per cell. Virions infect target cells with infection rate  and are cleared from serum with rate c. 
Anti-viral drugs are supposed to act mainly by blocking virion production, p, with effectiveness ε.  
Because c cannot be estimated when there is no viral load data during the first week of treatment, we 
fixed c = 6 day-1 as done previously.48  
Next the concentration effect relationship was modeled using an Emax model: 
        ( ) = 	
        ( )
  50        +         ( )
 
    ( ) = 	
    ( )
  50    +     ( )
 
where IC50ALV and IC50peg-IFN are concentrations of alisporivir and peg-IFN, respectively, needed to 
achieve an effectiveness of 50%. CALV(t) and Cpeg-IFN(t) are the drug concentrations predicted at time t.  
Lastly the total effectiveness of alisporivir and peg-IFN was modeled using a Bliss 
independence equation to describe the combined effectiveness of two drugs having independent 
mechanisms of action49: 
	 = 	1	–	(1 −    )	 1	 −	         
The effect of HCV genotypes was studied by including the covariate genotype1/4 (yes/no) on 
all VK parameters and treatment effectiveness. 
Individual mean effectiveness 
VK individual parameters were retrieved as the Empirical Bayes Estimates (EBEs). Then, the individual 
average effectiveness over a dosing interval [ti, tj] is defined by: 
 |̅  
   = 	
∫  ( )  
  
  
   −   
 
Statistical models 
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Let f the function describing the structural model, the statistical model for the observation Oij (drug 
concentrations or log10 viral loads) of subjects i at time tij is: 
    =     ,      +     
wherei is the vector of parameters of subject i and eij is the residual error.  
 The individual parameters i are supposed to follow log-normal distribution: 
   =   exp(     ×     ) exp	(  ) 
or logit-normal distribution (for the bioavailability parameter): 
   =
 
  + (1 −  ) exp(−     ×     ) exp(−  )
 
where µ is the fixed effects, representing population values, cov is the covariate effect, COVi is the 
binary covariate (treatment combination or genotype 1/4) and i is the random effect, supposed to follow 
N(0, ²). 
 The residual error eij were assumed to follow N(0, ²ij), where ²ij can be additive (   = 0)	, 
proportional (   = 0)	or combined model: 
   
  =     +       ,      
 
 
 We supposed a combined and an additive model for PK and VK error model, respectively. 
Parameter estimation 
Parameters were estimated using the SAEM algorithm implemented in MONOLIX 4.2.2 to handle data 
below LOQ. Models were compared using BIC values. Covariate was selected using stepwise method, 
based on p-value of likelihood ratio test. The likelihood was obtained using important sampling method. 
Only random effects correlations with a Pearson’s coefficient higher than 0.7 were tested. Standard 
goodness-of-fit plots, visual predictive checks, prediction discrepancies37–39 were used for model 
evaluation.  
External validation  
We evaluated the predictive ability of the PKVK model by comparing model predictions with the 
virologic responses obtained in patients genotype 2/3 in three alisporivir-containing arms of the VITAL-
1 study.5 All the three groups received a loading dose of 600 mg alisporivir BID for 1 week, followed 
by alisporivir 600 mg QD + Ribavirin (ribavirin) (arm VITAL-1b, N=84), alisporivir 800 mg QD + 
ribavirin (arm VITAL-1c, N=94) and alisporivir 600 mg QD + peg-IFN (arm VITAL-1d, N=39). 
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Patients with RVR, i.e., HCV RNA below LOQ (<25 IU/mL) at treatment week 4, continued the same 
treatment until week 24, while non-RVR patients switched to alisporivir 600 mg QD plus peg-
IFN/ribavirin from week 6 to week 24. Of note, the VITAL-1 study also comprised a group treated with 
alisporivir monotherapy. But a large proportion of patients developed non-PK related suboptimal 
response which requires other mechanism (e.g. resistance) to be incorporated.22 Thus this arm was 
excluded from our simulation. 
We used the PK-VK model (including residual errors) to simulate the virologic responses in the 
three alisporivir-containing arms of VITAL-1, considering the adaptive treatment and the number of 
patients retained in per protocol analysis. We assumed 100% treatment adherence and considered that 
ribavirin could prevent the growth of resistant viruses but had no effect on drug sensitive viruses44, i.e., 
we simulated alisporivir/ribavirin co-treatment using only the PKVK model of alisporivir. For each 
simulated patient, viral eradication (i.e., SVR) was considered attained if the model predicted less than 
1 virion or infected cells in the whole extracellular fluid volume, i.e., 6.7x10-5 copy(cell)/mL, during 
treatment period.46  
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Study Highlights 
What is the current knowledge on the topic? 
Alisporivir is a host-targeting agent against HCV currently in phase 3 of clinical development. In a phase 
2 dose-ranging study, the combination of alisporivir/peg-IFN for 28 days led to a rapid virologic decline 
for various HCV genotypes.  
What question does this study address? 
We built a pharmacokinetic/viral kinetic model to estimate antiviral effectiveness of alisporivir and peg-
IFN and predicted the virologic responses with other therapeutic strategies.  
What this study adds to our knowledge? 
This pharmacokinetic/viral kinetic model accounted for PK/PD interactions in drug combination in 
HCV. Alisporivir is highly effective at doses higher than 600 mg QD and acts additively with peg-IFN 
without evidence of synergism. Alisporivir effectiveness was not found to be significantly different 
across genotypes. Faster virologic response in genotype-2/3 patients was due to a more elevated loss 
rate of infected cells and higher sensitivity to peg-IFN.  
How this might change clinical pharmacology and therapeutics? 
This study showed that model from early viral kinetics could be useful to predict treatment outcome and 
anticipate future clinical studies.  
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Figure 1. Spaghettiplots of drugs concentration over time. 
Upper row: Spaghettiplots of alisporivir concentration over time in different treatment arms (Arm A - 
straight line and triangular, Arm B - straight line and diamond, Arm C - straight line and cross, Arm D 
- dashed line and cross) in the whole study period (left), on the first day (middle) and on the last day of 
treatment (right) 
Last row: Spaghettiplots of peg-IFN concentration over time in different treatment arms (Arm A - 
straight line and triangular, Arm B - straight line and diamond, Arm C - straight line and cross, Arm 
PEG - dashed line and circle) in the whole study period (left), on the first day (middle) and on the last 
day of treatment (right) 
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Figure 2. Spaghettiplots of viral load over time in different treatment arms (Arm A - straight line and 
triangular, Arm B - straight line and diamond, Arm C - straight line and cross, Arm D - dashed line and 
cross, Arm PEG - dashed line and circle) in the whole study period  
20 
 
 
Figure 3. Some examples of individual fits for 5 treatment arms obtained with PK-VK model. Arm A 
(alisporivir 200 mg + peg-IFN 180µg): 1st row, Arm B (alisporivir 600 mg + peg-IFN 180µg): 2nd row, 
Arm C (alisporivir 1000 mg + peg-IFN 180µg): 3rd row, Arm D (alisporivir 1000 mg): 4th row, Arm Peg 
(peg-IFN 180 µg): last row. Fits for alisporivir PK, peg-IFN PK and viral load are presented on the 1st, 
21 
 
2nd and 3rd column, respectively. Observed data are presented as circle; data below the quantification 
limit are presented as star symbols. 
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Figure 4. Predicted concentrations of alisporivir and peg-IFN (upper pattern) and predicted virologic 
response in different treatment arms and in genotype 1/4 and genotype 2/3 patients (lower pattern), 
23 
 
evaluated as the median of 1000 simulations. Simulated profiles are presented in black, blue, orange, 
magenta, and green for Arm A (alisporivir 200 mg + peg-IFN), B (alisporivir 600 mg + peg-IFN), C 
(alisporivir 1000 mg + peg-IFN), D (alisporivir 1000 mg) and arm PEG (peg-IFN 180µg), respectively. 
Virologic responses were presented as solid lines and dashed lines in in genotype-1/4 patients and 
genotype-2/3 patients, respectively. 
 
Figure 5. Prediction discrepancies for the PK-VK model for different treatment arms. Dashed lines in 
blue represent 10th and 90th observed percentiles, dashed line in red represents the 50th observed 
percentile. Blue and pink shaded areas are the 95% prediction interval of the corresponding percentiles. 
Observed data are presented in blue; data below the quantification limit are presented in red. 
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Table legends 
Table 1. Parameter estimates for PK models of alisporivir, peg-IFN and for the PK-VK model 
Parameters Fixed effects Interindividual variability 
Estimates (RSE %)  (%) (RSE %) 
PK parameters of alisporivir   
Tlag (h) 0.453 (1) 5.1 (20) 
ka (h-1) 2.77 (15) 46.8 (25) 
k12 (h-1) 0.256 (9) 26.6 (31) 
k21 (h-1) 0.0419 (12) 54.6 (16) 
V (L) 294 (8) 36.1 (14) 
Vm (Peg-IFN = 1) (mg.h-1) 115 (24) 25.9 (41) 
Vm (Peg-IFN = 0) (mg.h-1) 55 (24) 
Km (Peg-IFN = 1) (mg.L-1) 2.44 (33) 39.3 (50) 
Km (Peg-IFN = 0) (mg.L-1) 0.64 (11) 
F0 0.27 0 (-) 
Finf 0.853 97.6 (21) 
kF (h-1) 0.0341 0 (-) 
cor(Vm,Km) - 0.26 (241) 
a (µg/L)  6.6 (11)  
p (%)  34.1 (4)  
PK parameters of peg-IFN   
ka (h-1) 0.0392 (12) 69.7 (13) 
V (L) 12 (5) 51.4 (11) 
k (h-1) 0.00603 (7) 27 (14) 
a (µg/L) 0.243 (26)  
p (%) 30.0 (5)  
VK parameters   
VL0 (IU.mL-1) 1.14 x 106 (20) 166 (9) 
c (day-1) 6 (-) 0 (-) 
 in GT-1/4 (day-1) 0.217 (8) 43.1 (9) 
 in GT-2/3 (day-1) 0.393 (9) 
 (mL.virion-1.day-1) 5.6 x 10-7 (2) 171 (13) 
IC50alv (µg.L-1) 43.4 (38) 276 (10) 
IC50peg in GT-1/4 (µg.L-1) 2.26 (43) 201 (13) 
IC50peg in GT-2/3 (µg.L-1) 0.146 (54) 
a (log10IU/mL) 0.366 (4) 
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Table 2. (1) Observed virologic response in VITAL-1 study; (2) Predicted virologic responses obtained by simulation using PK-VK population parameters 
(including residual errors for VK data). The response-adapted therapy and the number of patients remained in per protocol analysis were taken into account in 
simulation. Simulation was conducted assuming no ribavirin effect on virologic response and 100% adherence to treatment. 
 
(1) 
 
Observed % of patients below LOQ at Observed SVR (%) 
Week 2 Week 4 Week 6 Week 12 
VITAL-1b* (N=77) 22.0 37.0 50.0 99.0 91.0 
VITAL-1c* (N = 80) 20.0 42.0 45.0 98.0 91.0 
VITAL-1d* (N=35) 62.0 85.0 90.0 96.0 91.0 
(2) 
 
Predicted % of patients below LOQ** at  Predicted SVR for a 24-week treatment** (%) 
Week 2 Week 4 Week 6 Week 12 Based on viral load Based on infected cells 
VITAL-1b* (N=77) 
19.0 
(11.7 – 27.3) 
44.0 
(33.8 – 51.9) 
53.6 
(42.9 – 63.0) 
92.9 
(88.3 - 96.8) 
94.0 
(88.3 – 98.7) 
91.7 
(85.7 – 96.1) 
VITAL-1c* (N = 80) 
21.3 
(14.3 – 28.8) 
46.8 
(36.3 – 58.4) 
57.4 
(45.6 – 67.5) 
93.6 
(88.1 – 97.5) 
93.6 
(88.8 – 98.8) 
92.6 
(86.3 – 97.5) 
VITAL-1d* (N=35) 
61.5 
(42.9 – 74.3) 
87.2 
(74.3 – 95.8) 
92.3 
(84.2 – 100.0) 
96.2 
(89.9 - 100.0) 
94.9 
(88.6 - 100.0) 
94.9 
(87.1 – 100.0) 
*All the three groups of VITAL-1 study received a loading dose of 600 mg alisporivir BID for 1 week, followed by alisporivir 600 mg QD + ribavirin (arm VITAL-1b), 
alisporivir 800 mg QD + ribavirin (arm VITAL-1c) and alisporivir 600 mg QD + peg-IFN (arm VITAL-1d). Patients with RVR, i.e., HCV RNA below LOQ (<25 IU/mL) at 
treatment week 4 , continued on the same treatment until week 24, while non-RVR patients switched to alisporivir 600 mg QD plus peg-IFN/ribavirin from week 6 to week 
24. 
** Median (95% prediction interval) 
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Table S1. Patient baseline characteristics per treatment group 
 Arm A 
Alisporivir 
200 mg 
Peg-IFN 
(N=18) 
Arm B 
Alisporivir 
600 mg 
Peg-IFN 
(N=18) 
Arm C 
Alisporivir 
1000 mg 
Peg-IFN 
(N=18) 
Arm D 
Alisporivir 
1000 mg 
 
(N=18) 
Arm Peg 
 
 
Peg-IFN 
(N=18) 
Sex (% male) 61 61 72 44 50 
Age* (years) 27.5 (19-51) 32.0 (19-45) 40.0 (21-59) 38.5 (23-68) 34.5 (21-51) 
Body mass index* 
(kg/m2) 
24.5 (19-28) 23.8 (19-28) 24.4 (19-28) 24.7 (20-29) 23.1 (20-29) 
Genotypes (GT)      
 1A 3 4 2 2 1 
 1B 8 8 10 9 9 
 2A 0 0 1 1 0 
 2B 0 0 1 1 1 
 3 6 6 4 4  5 
 4 1 0 0 1  2 
HCV RNA* 
(log10IU/mL) 
     
 All 6.03 (5.1-7.1) 6.40 (4.5–7.4) 6.27 (4.0–7.6) 6.12 (3.9–7.2) 6.04 (4.1–7.2) 
 GT 1 & 4 5.80 (5.1-7.1) 6.46 (5.2–7.4) 6.45 (4.0–7.0) 6.23 (4.4–7.2) 5.93 (4.1–7.2) 
 GT 2 & 3 6.5 (5.2-7.0) 6.20 (4.5–7.2) 6.02 (5.2–7.6) 5.82 (3.9–6.7) 6.71 (5.5–7.1) 
Ethnic      
 Caucasian 18 18 16 17 17 
 Others 0 0 2 1 1 
*Median (range) 
Table S1. Comparison of structural PK models after last dose of alisporivir  
Data* Structural model -2LL BIC Proportional 
error 
Day 29 & 50 
Arm A, B, C 
(ALV + Peg-
IFN) 
Two-compartment model with linear elimination 4050 4093 0.32 
Three-compartment model with linear elimination 4048 4106 0.32 
Two-compartment model with Michaelis-Menten 
elimination (Vm,Km) 
4021 4071 0.31 
Two-compartment model with Michaelis-Menten 
elimination and lag time for absorption 
(model for day 29) 
3962 4020 0.25 
Two-compartment model with two eliminations 
(linear and Michaelis-Menten) and lag time for 
absorption 
3967 4032 0.25 
Two-compartment model with Michaelis-Menten 
elimination, lag time for absorption and nonlinear 
distribution 
3959 4024 0.27 
*333 observations obtained during the last dose (day 29 and 50) from 37 patients in arm A, B, C (ALV 200 mg, 600 mg or 
1000 mg + peg-IFN) were used to build the model for the last dose of ALV (for steady state PK) 
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Table S3. Comparison of structural PK models of ALVfor alisporivir  after first to last dose  with changes in PK 
parameters   
Data* Structural model -2LL BIC Proportional 
error 
Day 1 - day 
50 
Arm A, B, 
C, D 
 
Model of day 29 8212 8296 0.49 
with time-varying bioavalaibility 7863 7962 0.35 
with time-varying Vm 8054 8159 0.41 
with time-varying Km 8144 8249 0.45 
*672 observations from 39 patients with rich design in in arm A, B, C (ALV 200 mg, 600 mg or 1000 mg + peg-IFN) were 
used to build the structural PK model for ALV 
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Figure S1. Median of observed data and median predicted by the structural model for the last dose, obtained from 1000 
simulations, for the last dose (first row) and for the first dose (last row). This model over-predicted concentration obtained at 
the first dose of alisporivir 
 
Figure S2. Median of observed data and median predicted by the model for full PK data of three combination groups, obtained 
from 1000 simulations, for the first dose (first row) and for the last dose (last row) in the four treatment arm. This model over-
predicted alisporivir concentration at the last day of treatment in the monotherapy group. 
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Figure S3. VPC of the full PK model of alisporivir in four treatment arms after taking into account peg-IFN. Dashed lines in 
blue represent 10th and 90th percentiles of the observations; dashed line in red represents the 50th percentile of the observations. 
Blue and pink shaded areas are the 95% prediction interval of the corresponding percentiles. 
 
 
Figure S4. VPC for final alisporivir PK model for all study period (left pattern), day 1 (middle pattern) and the last day of 
treatment (right pattern). Dashed lines in blue represent 10th and 90th percentiles of the observations; dashed line in red 
represents the 50th percentile of the observations. Blue and pink shaded areas are the 95% prediction interval of the 
corresponding percentiles. 
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Figure S5. VPC for peg-IFN PK model for all study period (left pattern), day 1 (middle pattern) and the last day of treatment 
(right pattern). Dashed lines in blue represent 10th and 90th percentiles of the observations; dashed line in red represents the 50th 
percentile of the observations. Blue and pink shaded areas are the 95% prediction interval of the corresponding percentiles. 
 
 
Figure S6. VPC for the PK-VK model for all data (left pattern), for genotype-1/4 patients (middle pattern) and for genotype-
2/3 patients (right pattern). Dashed lines in blue represent 10th and 90th percentiles of the observations; dashed line in red 
represents the 50th percentile of the observations. Blue and pink shaded areas are the 95% prediction interval of the 
corresponding percentiles. Data below the quantification limit were presented as red closed circle. 
 
